| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | KIF11; EG5; KNSL1; TRIP5; Kinesin-like protein KIF11; Kinesin-like protein 1; Kinesin-like spindle protein HKSP; Kinesin-related motor protein Eg5; Thyroid receptor-interacting protein 5; TR-interacting protein 5; TRIP-5 |
| Entrez GeneID | 3832 |
| WB Predicted band size | Calculated MW: 119 kDa; Observed MW: 119 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human Eg5 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Eg5抗体的3篇参考文献示例(注：部分信息为示例性概括，实际文献请通过学术数据库验证)：
1. **文献名称**: "Targeting the mitotic kinesin Eg5 with monoclonal antibodies: a novel approach to cancer therapy"
**作者**: Smith, J. et al.
**摘要**: 该研究开发了针对Eg5的多种单克隆抗体，验证其在体外和动物模型中抑制肿瘤细胞增殖的能力，表明抗体通过阻断Eg5的ATP酶活性干扰有丝分裂进程。
2. **文献名称**: "Structural basis of Eg5 inhibition by a selective antibody fragment"
**作者**: Li, H. & Wang, Y.
**摘要**: 通过X射线晶体学解析了Eg5蛋白与特异性抗体Fab片段的复合物结构，揭示了抗体结合位点位于Eg5的motor结构域，为优化靶向抑制剂提供结构依据。
3. **文献名称**: "Resistance mechanisms to Eg5-targeting antibodies in colorectal cancer models"
**作者**: Garcia, R. et al.
**摘要**: 研究指出结直肠癌细胞可通过上调βIII-tubulin表达和激活MAPK通路对Eg5抗体产生耐药性，提示联合靶向治疗策略的必要性。
4. **文献名称**: "Phase I trial of anti-Eg5 humanized monoclonal antibody in solid tumors"
**作者**: Brown, K. et al.
**摘要**: 首次人体临床试验显示，人源化Eg5抗体在晚期实体瘤患者中耐受性良好，但客观缓解率较低(<10%)，提示需优化给药方案或生物标志物筛选。
**注意**：以上为模拟文献，实际研究请参考PubMed、Web of Science等平台的最新论文。Eg5靶点药物研发多集中于小分子抑制剂(如ispinesib)，单克隆抗体的相关文献相对较少，建议结合"KIF11 antibody therapy"等关键词扩展检索。
**Background of Eg5 Antibody**
Eg5 (kinesin family member 11. KIF11) is a mitotic kinesin critical for spindle pole separation during early mitosis. It plays a key role in forming the bipolar spindle, ensuring accurate chromosome segregation. Due to its restricted expression in proliferating cells, Eg5 emerged as an attractive anticancer target, as its inhibition selectively disrupts mitosis in rapidly dividing cancer cells while sparing non-dividing healthy cells.
In the early 2000s, small-molecule Eg5 inhibitors (e.g., ispinesib, filanesib) entered clinical trials, aiming to exploit this mechanism. However, challenges like limited efficacy, toxicity, or drug resistance slowed their progress. Meanwhile, Eg5 antibodies gained attention as research tools to study mitotic regulation and potential therapeutic agents. These antibodies often target Eg5's motor domain, blocking its ATPase activity or microtubule-binding ability, thereby inducing mitotic arrest and apoptosis in cancer cells.
Recent studies explore Eg5 antibodies in combination therapies or as diagnostics to monitor Eg5 expression in tumors. Despite hurdles, Eg5 remains a focus in oncology, reflecting its unique role in cell division and the ongoing pursuit of mitosis-targeted cancer treatments.
×
